Clinical Mass Spectrometry Market - By Technological Advancements & Competitive Insights 2019-2027

The Global Clinical Mass Spectrometry Market, by product type (GAS Chromatography-Mass Spectrometry, Instrument, Liquid Chromatography-Mass Spectrometry, Instrument, MALDI TOF Mass Spectrometer, Capillary Electrophoresis-Mass Spectrometry, and Ion Mobility Spectrometry-Mass Spectrometry), by application (Clinical Testing, Proteomics, and Drug Discovery), and by end user (Hospitals, Research Laboratories, and Diagnostic Laboratories) was valued at US$ 4,665.3 million in 2016 and is projected to exhibit a CAGR of 7.3% over the forecast period (2017-2025), as highlighted in a new report published by Coherent Market Insights. Focus of key players on development of products through advanced technology and rising prevalence of lifestyle related diseases are attributed to drive meteoric growth of the clinical mass spectrometry market over the forecast period.
Clinical mass spectrometry is widely used in the detection of chemotherapy protein markers, targeted therapy protein markers, and diagnostic protein markers. Increasing application of mass spectrometry in translational research is widening the scope for discovery with respect to blood-based biomarkers, tumor markers, and new disease markers. Endocrinologists are focusing on research related to 'lab on a plate' method for more accurate prediction of risk of heart attack and stroke for diabetic patients. Tissue imaging requires neural architecture examination at the primary level, for which mass spectrometry provides much higher data than conventional stain based histology leading to even more adoption of the technique.
Clinical mass spectrometric analysis provides direct administration of diagnostic data, which helps in the effective to management and planning of treatment. Thus, integration of mass spectrometric data analysis results in the laboratory information system (LIS), in turn boosting growth of the market to grow in the near future. Moreover, the mass spectrometers facilitating automatic processing without the requirement of a technical expertise allows for integration of automation, creating highly lucrative growth opportunities for market players.
Browse 34 Market Data Tables and 27 Figures spread through 171 Pages and in-depth TOC on ""Clinical Mass Spectrometry Market, by Product Type (GAS Chromatography-Mass Spectrometry-(GC MS) Instrument, Liquid Chromatography-Mass Spectrometry-(GC MS) Instrument, MALDI TOF Mass Spectrometer, Capillary Electrophoresis-Mass Spectrometry and Ion Mobility Spectrometry-Mass Spectrometry), by Application (Clinical Testing, Proteomics and Drug Discovery), and by End User (Hospitals, Research Laboratories and Diagnostic Laboratories), and Region - Global Forecast to 2025""
Asia Pacific is expected to witness maximum growth in the global clinical spectrometry market, owing to advancements in biotechnology and life sciences sector in this region as well as the focused expansion and massive investments by leading market players in these regions. For instance, Agilent Tech invested US$ 85 Mn over the last five years in research and manufacturing at its Singapore facility, for the production of high-end analytical instruments, especially mass spectrometers due to increasing demand for these instruments in the Asia Pacific countries.
The healthcare facilities and services in the Middle East are growing at a slow pace, however, the region has high potential to emerge as a robust infrastructure in the near future. Countries in the region are thus, forming alliances with the global leading companies as well as government organizations to foster the development of healthcare. For instance, the American Association of Clinical Chemistry (AACC) partnered with Al Borg Medical Laboratories in 2017, in Abu Dhabi, to provide gold standard, actionable information to advance patient care and health improvement with the use of analytical tools such as liquid chromatography mass spectrometry (LC-MS).
Vendors are continuously investing in the development of clinical mass spectrometry for various applications in clinical and translational research, which is projected to experience lucrative growth over the forecast period. In 2016, Bruker launched a number of new mass spectrometry-based product solutions, including timsTOF, which is a research grade instrument for optimal separation and analysis of unresolved compounds and conformations.
Key takeaways of the Clinical Mass Spectrometry Market:
• The global clinical mass spectrometry market is expected to exhibit a CAGR of 3% over the forecast period
• Among product type, growth of the liquid chromatography-mass spectrometry-(LC MS) segment is higher than that of gas chromatography-mass spectrometry-(GC MS) segment, owing to better detection of small molecules, especially protein biomarkers with higher immunoassay accuracy
• MALDI TOF mass spectrometer segment is also expected to witness rapid grow over the forecast period, as it supports direct tissue analysis with diagnostic potential and reduced analysis time
• Among application, the clinical testing segment holds a leading position in the market , as this is an emerging field and a wide range of laboratory developed tests (LDTs) are based on mass spectrometry
• Some of the major players involved in global clinical mass spectrometry market are Agilent Technologies, Waters, Shimadzu Corporation, Danaher, PerkinElmer Inc., Thermo Fisher Scientific Inc., Bruker, Mass Spectrometry Instruments (MSI), and Kore technology.